118839-23-9

Basic information

• Product Name: N-(β-bromo-phenethyl)-phthalimide
• Synonyms: N-(β-bromo-phenethyl)-phthalimide
• CAS NO: 118839-23-9
• Molecular Weight: 330.181
• Mol File: 118839-23-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(β-bromo-phenethyl)-phthalimide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(β-bromo-phenethyl)-phthalimide(118839-23-9)
• EPA Substance Registry System: N-(β-bromo-phenethyl)-phthalimide(118839-23-9)

Safety Data

• Hazardous Substances Data: 118839-23-9(Hazardous Substances Data)

Upstream product

• 1074-82-4 potassium phtalimide 
• 103-64-0 bromostyrene 
• 64-04-0 phenethylamine 
• 85-44-9 phthalic anhydride 
• 7501-05-5 N-(2-phenylethyl)phthalimide 
• 23092-87-7 2-[(E)-2-phenylvinyl]-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 10035-10-6 hydrogen bromide 
• 136613-13-3 2-[(Z)-2-phenylvinyl]-1H-isoindole-1,3(2H)-dione 
• 23092-87-7 2-[(E)-2-phenylvinyl]-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor α

Benzylphthalimide analogs (P1P's) and phenethylphthalimide analogs (P2P's) have been found to exhibit thalidomide-like activity on the production of tumor necrosis factor (TNF)-α by the human leukemia cell line, HL-60, stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA). Structure-activity relationships are discussed on the basis of the TNF-α production-enhancing activity. Benzylphthalimide (P1P-00) exhibited activity which is weaker than that of thalidomide, but introduction of a methyl group at the ortho-position of the benzyl moiety (P1P-10) resulted an increase to a level comparable with that of thalidomide. Phenethylphthalimide (P2P-00) is more potent than thalidomide, and its fluorinated derivative, 2-phenethyl-4,5,6,7-tetrafluoro- 1H-isoindole-1,3-dione (FP2P-00), exhibited potent activity at very low concentrations.

Substituted amine derivatives, their production and use

Substituted amino derivatives represented by the formula: STR1 wherein R1 and R2 each stand for an acyclic hydrocarbon residue or an alicyclic hydrocarbon residue; R3 and R4 each stand for hydrogen or a hydrocarbon residue optionally containing hetero-atom(s); A stands for a carbon chain having two or more carbon atoms optionally containing ether linkage or sulfide linkage, which may be substituted and which may per se form a ring; X1 and X2 each stand for oxygen atom or sulfur atom; and Y stands for amino group or an organic residue bonded through nitrogen atom, which may form a ring by combining with a carbon atom constituting A; and their salts have anti-arrhythmic activity and are useful for prevention and treatment of a variety of arrhythmias.